Pulmonx

Pulmonx focuses on minimally invasive treatments for severe lung disease. The company’s platforms are designed to assess and treat patients with severe emphysema and chronic obstructive pulmonary disease who, despite medical management, are still symptomatic. Pulmonx completed its IPO on the Nasdaq stock market in October 2020.